Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial

Ocular Therapeutix Inc OCUL announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.

• The clinical trial achieved its pre-specified primary endpoint, demonstrating a statistically significant change of bulbar conjunctival hyperemia from baseline to day 15 compared to vehicle hydrogel.
• The differences were statistically significant compared with the vehicle hydrogel for both the OTX-DED 0.2 mg group and the OTX-DED 0.3 mg group. 
• OTX-DED inserts (both formulations) were observed to have a favorable safety profile and were generally well tolerated. 
• There were no ocular serious adverse events. 
• The most common ocular adverse events for subjects treated with OTX-DED were epiphora (lacrimation increase) (8.1%) and elevated intraocular pressure (IOP) (3.6%). 
• Read Next: Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati.
• Price Action: OCUL shares are up 0.32% at $6.18 during the market session on the last check Monday.